TPS4217 Background: IL-27 is a heterodimerized cytokine, a member of the IL-12/IL-23 cytokine family, and an immunoregulatory cytokine expressed by myeloid cells that dampens T and NK effector function. IL-27 is highly expressed by tumor-associated macrophages in several cancers, including hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC), and suppresses antitumor immune responses. Casdozokitug (Casdozo) is the only clinical-stage IL-27 targeting antibody and it increases IFN-g and T and NK cell activation in preclinical/clinical studies. A phase 1 study (NCT04374877) demonstrated a favorable safety profile and antitumor activity of casdozo as monotherapy and in combination with PD-1 blockade in indications, including HCC, with known high levels of IL-27 activation signature (Marron T, et al. Ann Oncol . 2023). A phase 3 study of toripalimab (tori) + bevacizumab (bev) demonstrated significant improvements in efficacy (overall survival [OS], progression-free survival [PFS], and objective response rate [ORR]) compared to sorafenib (Yinghong S, et al. CSCO 2024) in HCC. A phase 2 study of casdozo + atezolizumab + bev showed an acceptable safety profile and antitumor activity (ORR 38%, CR 17.2%, mPFS 8.1 mo) (Li D, et al. ASCO GI 2025). CHS-388-202 (NCT06679985) will evaluate the efficacy, safety, and biomarkers of tori + bev ± casdozo and optimize the dose for casdozo in combination with tori + bev as first-line treatment for patients (pts) with unresectable and/or locally advanced/metastatic HCC. Methods: CHS-388-202 is a Phase 2, open-label, randomized study and will enroll up to 72 pts randomized (1:1:1) to 1 of 3 treatment arms (IV Q3W): Arm A (tori 240 mg + bev 15 mg/kg + casdozo 700 mg), Arm B (tori 240 mg + bev 15 mg/kg + casdozo 1400 mg), Arm C (tori 240 mg + bev 15 mg/kg). Key eligibility criteria include treatment-naïve unresectable metastatic HCC with ≥1 measurable lesion; not suitable for surgical or local therapy; Child-Pugh A; ECOG PS 0 or 1; controlled hepatitis B virus or cured hepatitis C virus. Pts will be stratified by geographic region (Asia excluding Japan vs the rest of the world) and macrovascular invasion or extrahepatic spread of disease (presence vs absence). Primary endpoints are ORR by investigator review according to RECIST v1.1 and safety. Secondary endpoints are ORR by investigator review according to HCC modified RECIST (mRECIST) criteria; duration of response, PFS, and disease control rate by investigator review according to RECIST v1.1 and mRECIST criteria; OS, pharmacokinetics. A safety run-in evaluation will be conducted after the first ~6 pts are enrolled in Arms A and B, with ≥3 from each arm completing 1 cycle of treatment. Pts will remain on study treatment for ≤2 years or until documented disease progression or unacceptable toxicity. Enrollment is ongoing. Clinical trial information: NCT06679985 .
1506 Background: Typical workflows for clinical trial start-up and screening are time- and resource-intensive. The Tempus AI TIME program offers a novel clinical trial solution, collaborating with clinical sites to increase trial access and alleviate site burden by streamlining study activation and screening methods. Methods: The TIME program consists of an algorithmic trial screening platform (TApp), team of oncology nurses, diverse trial portfolio, and rapid study activation processes. Patient-level clinical information is centralized within the TIME database and includes structured and unstructured data generated from Electronic Medical Record integration, next generation sequencing results, and natural language processing models. The TApp used this data combined with trial eligibility criteria to algorithmically match patients to TIME trials. TApp searches were triggered by changes to study criteria and/or updates to clinical data. Algorithmic matches were filtered based on site capabilities, site interest in the trial, and trial lookback criteria, which defined the required recency of a patient's latest clinical document or encounter. Qualifying matches were then reviewed by a Tempus nurse and sent to sites if confirmed eligible. Trial activations followed TIME’s streamlined operational methods using a pre-negotiated rate card for site reimbursement of all clinical trial activities, standardized clinical trial agreement, and central IRB. Trials could be activated prospectively before the first eligible patient was identified, or in a “just-in-time” (JIT) manner if a patient was ready to consent. Data collected included TIME network information, TApp and nurse screening results, activation timelines, and enrollments across all active TIME sites and trials from 01/01/2024 - 12/31/2024. Results: During 2024, the TIME network consisted of 87 sites (79 Community, 8 Academic) and 98 trials. The TApp completed 1,323,259,353 searches across 1,281,676 patients resulting in 2,251,505 potential TApp trial matches. After applying site capability and trial lookback filters, TIME nurses screened 35,912 of these matches with 5,034 confirmed. These matches led to 186 activations (82 JIT, 104 prospective) and 573 consents. Conclusions: The Tempus AI TIME program facilitated the screening of 1.28M+ patients for over 95 clinical trials, averaging 1.57 consents per day over 1 year. Future trial matching strategies should utilize algorithmic screening and rapid activation processes to improve patient access and trial success. 2024 patient screening and consents. Patient Population 1,281,676 TIME Trials 98 TApp Searches 1,323,259,353 Algorithmic Matches 2,251,505 Matches Screened 35,912 Matches Confirmed 5,034 Interventional Consents 225 Observational Consents 348 Total Activations JIT: 82, Prospective: 104 Avg Activation Time (business days) JIT: 16.1, Prospective: 39.6
TPS12142 Background: Cachexia is a complex and common cancer comorbidity associated with a high risk of death. Despite its significant impact, no FDA-approved therapies exist to treat cancer cachexia, and current off-label treatments are limited and increase the risk of side effects. Circulating GDF-15, an inflammatory cytokine involved in the stress response and body weight regulation, has emerged as a main modulator implicated in the pathogenesis of cachexia. Further, preclinical models have shown that elevated levels of circulating GDF-15 elicit cachexia, and GDF-15 expression increases in proportion to disease severity. AV-380 is a high-affinity anti-GDF-15 IgG1 monoclonal antibody resulting in circulating GDF-15 elimination. AV-380 has been shown to reverse weight loss and increase muscle recovery in animal cancer models. In a phase 1 healthy volunteer study (in-house data), AV-380 was well-tolerated without serious AEs. Methods: This is an open-label, dose-escalation, multicenter phase 1b study to assess the safety, tolerability, PK, and PD of AV-380. Eligible patients must be ≥18 years of age, have cancer with cachexia (per international consensus criteria), receive standard-of-care antineoplastic therapy, have a prognosis of ≥3 months, and have an ECOG PS ≤2. Patients with known brain metastases (unless treated and stable for ≥2 weeks), myocardial infarction or grade 3/4 heart failure (≤3 months), uncontrolled third-spacing of fluids (pleural effusion, pericardial effusion, and/or ascites), or non-cancer-related cachexia, are excluded. Primary endpoints will evaluate the safety and tolerability per dose-limiting toxicities, adverse events (NCI CTCAE v5), and laboratory test results. Secondary endpoints include PK analysis, and exploratory endpoints include anti-drug antibodies, weight changes, patient-reported outcomes (Functional Assessment of Anorexia Cachexia Therapy, Patient Global Impression of Severity, Patient’s Global Impression of Change, Patient-Reported Outcomes Measurement Information System) physical function (by digital measures), and body composition (Lumbar 3 Skeletal Muscle Index). Escalating dose cohorts of AV-380 consist of 3-6 patients each, following a standard 3+3 design. The treatment is structured into 28-day courses for each cohort. AV-380 will be administered by IV infusion. Patients will remain on AV-380 until they have unacceptable toxicity, complete 4 courses, withdraw consent, or the sponsor terminates the study. Statistical analyses will be completed by cohort and summarized descriptively. Clinical trial information: NCT05865535 .
Engaging professionals from all areas of computing, the IEEE Computer Society sets the standard for education and engagement that fuels global technological advancement.Through conferences, publications, and programs, IEEE CS empowers, guides, and shapes the future of its members, and the greater industry, enabling new opportunities to better serve our world.
Cellular senescence, the aging of cells, is a multifaceted process characterized by the progressive accumulation of molecular and cellular changes. Senescent cells, marked by their proinflammatory secretome called the senescence-associated secretory phenotype (SASP), contribute to tissue dysfunction and promote aging processes. In this review, we provide a comprehensive overview of the current understanding of cellular senescence, with a particular focus on the underlying mechanisms driving cell aging and the strategies of targeting senescent cells to extend healthspan and alleviate age-related diseases. We discuss how factors such as telomere shortening, DNA damage, oxidative stress, and oncogene activation contribute to cellular aging and the development of age-related diseases. Furthermore, we explore the potential senotherapeutic interventions, including senolytic and senomorphic therapies, that target senescent cells. Lastly, we highlight the opportunities and challenges of senotherapeutics in the context of aging and aging-associated diseases, underscoring their potential implications for human health and longevity.